Online Platform for Liquid Biopsy Services

The latest developments in the field of liquid biopsy are set to revolutionise cancer diagnosis, treatment, and monitoring, as highlighted in the upcoming Liquid Biopsy ONLINE webinar series. This cutting-edge online event, taking place from 14th to 28th November, will delve into the latest methods and innovations improving the sensitivity, reliability, and clinical utility of liquid biopsies.

The series, consisting of three parts, will kick off on Tuesday, 14th November at 3pm GMT / 4pm CET / 10am EST, with a focus on leveraging liquid biopsy for a more personalised approach to cancer treatment and monitoring. The first webinar will feature talks by Naureen Starling from The Royal Marsden Hospital and Jaclyn Biegel from Children's Hospital Los Angeles.

The second webinar, scheduled for Tuesday, 21st November, will explore the topic of "Joining Forces: Liquid Biopsies and MRD Detection in Colorectal and Hematologic Cancers." Sara Lonardi from Veneto Institute of Oncology IOV - IRCCS Padua, Italy will present the PEGASUS Trial, which defines the clinical utility of liquid biopsy for MRD detection in colon cancer. Paul Hofman from Nice Sophia Antipolis University will also present clinical considerations for the implementation of liquid biopsy testing in lung cancer patients.

The third and final webinar, titled "Overcoming Challenges and Establishing the Clinical Utility of Liquid Biopsies," will take place on Tuesday, 28th November at 3pm GMT / 4pm CET / 10am EST. Pashtoon Kasi from Weill Cornell Medicine will present a talk titled "Monitoring MRD in Colorectal Cancer to Advance Precision Medicine." Viktor Adalsteinsson from the Broad Institute will discuss injectable priming agents and sequencing technology innovations to improve liquid biopsy testing. Miguel García-Pardo from Hospital Universitario Ramón y Cajal, Madrid will present a talk on the "Plasma-first" Approach for Molecular Genotyping in Non-small Cell Lung Cancer: opportunities and challenges.

Registration for one webinar in the series grants access to all subsequent webinars in the series. The series will cover the use of liquid biopsies in clinical studies for therapy monitoring, treatment selection, and MRD detection. It will also discuss considerations that need to be addressed as liquid biopsies enter prime time for clinical use.

The latest developments in liquid biopsy applications for precision oncology, as emphasised in recent expert discussions including the Liquid Biopsy ONLINE webinar series, underscore the significant advances in early cancer detection, treatment monitoring, and personalised therapy guidance. A cutting-edge liquid biopsy test using RNA modifications has demonstrated 95% accuracy in detecting early-stage colorectal cancer, overcoming the traditional challenge of low circulating tumor DNA (ctDNA) levels in early disease.

These non-invasive techniques support longitudinal disease monitoring and precision medicine approaches by identifying actionable mutations and molecular relapse earlier than conventional methods. However, challenges remain, including optimising the frequency and duration of ctDNA monitoring, cost-effectiveness, and demonstrating survival benefits beyond delaying progression.

The liquid biopsy market is rapidly growing, driven by innovations in epigenomic methylation profiling, machine learning, and multi-cancer early detection platforms like Galleri, which has gained FDA Breakthrough Device Designation and is integrated into national screening programs. These developments underscore liquid biopsy's increasing role in non-invasive cancer detection, prognosis, and personalised treatment management.

In summary, the Liquid Biopsy ONLINE webinar series and recent literature highlight that liquid biopsy is evolving into a powerful tool in precision oncology by enabling sensitive early detection, dynamic disease monitoring, and tailored therapeutic strategies, although ongoing research is needed to address clinical implementation challenges and fully realise survival benefits.

[1] [Source] [2] [Source] [3] [Source] [4] [Source]

The upcoming Liquid Biopsy ONLINE webinar series will delve into the latest methods and innovations improving the sensitivity, reliability, and clinical utility of liquid biopsies.
The webinar series will focus on leveraging liquid biopsy for a more personalized approach to cancer treatment and monitoring.
Sara Lonardi from Veneto Institute of Oncology IOV - IRCCS Padua, Italy will present the PEGASUS Trial, which defines the clinical utility of liquid biopsy for MRD detection in colon cancer.
The latest developments in liquid biopsy applications for precision oncology have demonstrated 95% accuracy in detecting early-stage colorectal cancer.
The liquid biopsy market is rapidly growing, driven by innovations in epigenomic methylation profiling, machine learning, and multi-cancer early detection platforms.
A cutting-edge liquid biopsy test using RNA modifications supports longitudinal disease monitoring and precision medicine approaches by identifying actionable mutations and molecular relapse earlier than conventional methods.
Ongoing research is needed to address clinical implementation challenges and fully realise survival benefits with liquid biopsy.
These developments underscore liquid biopsy's increasing role in non-invasive cancer detection, prognosis, and personalised treatment management. [1, 2, 3, 4 contain sources for further reading]